CR20160516A - Proteínas agonistas de los receptores de trail de cadena simple - Google Patents

Proteínas agonistas de los receptores de trail de cadena simple

Info

Publication number
CR20160516A
CR20160516A CR20160516A CR20160516A CR20160516A CR 20160516 A CR20160516 A CR 20160516A CR 20160516 A CR20160516 A CR 20160516A CR 20160516 A CR20160516 A CR 20160516A CR 20160516 A CR20160516 A CR 20160516A
Authority
CR
Costa Rica
Prior art keywords
agonist proteins
trail receptors
single chain
trail
proteins
Prior art date
Application number
CR20160516A
Other languages
English (en)
Inventor
Oliver Hill
Meinolf Thiemann
Christian Gieffers
Darren Phillips
Susan Lappe
Fritz Buchanan
Original Assignee
Apogenix Ag
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apogenix Ag, Abbvie Inc filed Critical Apogenix Ag
Publication of CR20160516A publication Critical patent/CR20160516A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)

Abstract

Proteínas específicas que son agonistas de los receptores de TRAIL. Ácidos nucleicos que las codifican. Métodos para tratar una enfermedad o un trastorno asociado a los TRAIL en un sujeto. Las proteínas agonistas de los receptores de TRAIL que se proveen en la presente comprenden tres dominios de TRAIL solubles y un fragmento Fc. Las proteínas agonistas de los receptores de TRAIL no forman agregados de manera sustancial y son apropiadas para aplicaciones terapéuticas, de diagnóstico y/o de investigación.
CR20160516A 2014-04-23 2015-04-23 Proteínas agonistas de los receptores de trail de cadena simple CR20160516A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461983152P 2014-04-23 2014-04-23
PCT/US2015/027270 WO2015164588A1 (en) 2014-04-23 2015-04-23 Single-chain trail-receptor agonist proteins

Publications (1)

Publication Number Publication Date
CR20160516A true CR20160516A (es) 2017-05-10

Family

ID=53055121

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20160516A CR20160516A (es) 2014-04-23 2015-04-23 Proteínas agonistas de los receptores de trail de cadena simple

Country Status (37)

Country Link
US (4) US9908927B2 (es)
EP (2) EP3134430B1 (es)
JP (2) JP6523331B2 (es)
KR (2) KR102079919B1 (es)
CN (2) CN106459221B (es)
AR (1) AR100168A1 (es)
AU (3) AU2015249649B2 (es)
BR (1) BR112016024515B1 (es)
CA (2) CA2946402C (es)
CL (1) CL2016002683A1 (es)
CR (1) CR20160516A (es)
CY (1) CY1120281T1 (es)
DK (1) DK3134430T3 (es)
DO (1) DOP2016000284A (es)
EC (1) ECSP16089579A (es)
ES (1) ES2672368T3 (es)
HR (1) HRP20180950T1 (es)
HU (1) HUE038914T2 (es)
IL (2) IL248244B (es)
LT (1) LT3134430T (es)
MA (2) MA39770A (es)
MX (2) MX2016013858A (es)
MY (1) MY181986A (es)
NO (1) NO2776305T3 (es)
PE (1) PE20170299A1 (es)
PH (1) PH12016502079A1 (es)
PL (1) PL3134430T3 (es)
PT (1) PT3134430T (es)
RS (1) RS57153B1 (es)
RU (1) RU2699285C2 (es)
SG (3) SG11201608767XA (es)
SI (1) SI3134430T1 (es)
TR (1) TR201806912T4 (es)
TW (2) TWI747178B (es)
UA (1) UA118286C2 (es)
UY (1) UY36095A (es)
WO (1) WO2015164588A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170138585A (ko) 2015-05-04 2017-12-15 아포게닉스 아게 단일-쇄 cd40-수용체 작용제 단백질
CN108430492B (zh) 2015-10-23 2022-05-03 阿珀吉科吉尼科斯股份公司 单链cd27受体激动剂蛋白
EP3365361A1 (en) * 2015-10-23 2018-08-29 Apogenix AG Single-chain light receptor agonist proteins
EP3365363A1 (en) * 2015-10-23 2018-08-29 Apogenix AG Single-chain gitr-receptor agonist proteins
WO2017102010A1 (en) * 2015-12-17 2017-06-22 Biontech Rna Pharmaceuticals Gmbh Novel cytokine fusion proteins
US10821160B2 (en) 2016-03-01 2020-11-03 The Board Of Trustees Of The University Of Illinois L-asparaginase variants and fusion proteins with reduced L-glutaminase activity and enhanced stability
CA3017622A1 (en) * 2016-03-16 2017-09-21 Merrimack Pharmaceuticals, Inc. Engineered trail for cancer therapy
US10501744B2 (en) 2016-05-04 2019-12-10 Indiana University Research And Technology Corporation Presentation of bioactive proteins
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Hdac抑制劑與pd-l1抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
EP3468580A4 (en) * 2016-06-13 2020-02-26 Merrimack Pharmaceuticals, Inc. METHODS OF SELECTING AND TREATING PATIENTS WITH A CELL DEATH RECEPTOR AGONIST OR A TRAIL-BASED THERAPEUTIC COMPOUND
EP3360898A1 (en) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
AU2018313253A1 (en) * 2017-08-11 2020-02-27 The Board Of Trustees Of The University Of Illinois Truncated guinea pig L-asparaginase variants and methods of use
TW202002952A (zh) * 2018-03-15 2020-01-16 美商艾伯維有限公司 用於治療胰臟癌之abbv-621與抗癌劑之組合
TW202003553A (zh) * 2018-03-15 2020-01-16 美商艾伯維有限公司 用於治療癌症之abbv-621與抗癌劑之組合
US20230212260A1 (en) 2020-05-15 2023-07-06 Apogenix Ag Multi-specific immune modulators
WO2022248662A1 (en) 2021-05-28 2022-12-01 Julius-Maximilians-Universität Würzburg Recombinant proteinaceous binding molecules
WO2023088876A1 (en) 2021-11-16 2023-05-25 Apogenix Ag Multi-specific immune modulators

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1226173A1 (en) 1999-10-07 2002-07-31 Maxygen Aps Single-chain antagonist polypeptides
DE19963859A1 (de) 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
CA2314199A1 (en) 2000-07-21 2002-01-21 Robert Simoneau C-chip
CA2716959A1 (en) 2000-12-07 2002-06-13 Eli Lilly And Company Glp-1 fusion proteins
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7538088B2 (en) 2002-04-26 2009-05-26 California Institute Of Technology Method for inhibiting angiogenesis by administration of the extracellular domain of D1-1 polypeptide
DE102004014983A1 (de) 2004-03-26 2005-10-20 Univ Stuttgart Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
US20060188498A1 (en) * 2005-02-18 2006-08-24 Genentech, Inc. Methods of using death receptor agonists and EGFR inhibitors
EP1871798B1 (en) * 2005-04-15 2009-10-14 Rappaport Family Institute For Research in the Medical Sciences Molecules and methods of using same for treating mcp-1/ccr2 associated diseases
US8008443B2 (en) 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
EP1894940A1 (en) 2006-08-28 2008-03-05 Apogenix GmbH TNF superfamily fusion proteins
US8383774B2 (en) 2007-07-10 2013-02-26 Apogenix Gmbh Collectin fusion proteins comprising TNF or trail
BRPI0913406A2 (pt) 2008-06-03 2018-01-09 Abbott Lab imunoglobulinas de domínio variável duplo e usos das mesmas
PL2310509T3 (pl) 2008-07-21 2015-08-31 Apogenix Ag Jednołańcuchowe cząsteczki TNFSF
MX2011002759A (es) * 2008-09-22 2011-07-28 Amgen Inc Metodo de tratamiento.
AU2009303304A1 (en) * 2008-10-10 2010-04-15 Anaphore, Inc. Polypeptides that bind TRAIL-RI and TRAIL-R2
EP2829550B1 (en) 2009-01-09 2016-11-16 Apogenix AG Fusion proteins forming trimers
AU2010206681A1 (en) * 2009-01-23 2011-09-01 Biogen Idec Ma Inc. Stabilized Fc polypeptides with reduced effector function and methods of use
US20130011401A1 (en) 2009-12-22 2013-01-10 Novartis Ag Soluble proteins for use as therapeutics
KR101747991B1 (ko) 2010-04-13 2017-06-19 메디뮨 엘엘씨 Trail r2 특이적 다량체 스캐폴드
EP2793949B1 (en) * 2011-12-23 2018-08-22 Innate Pharma Enzymatic conjugation of antibodies
EP3406630B1 (en) * 2012-07-18 2020-09-02 Apogenix AG Artificial signal peptide

Also Published As

Publication number Publication date
US20180222962A1 (en) 2018-08-09
TWI683825B (zh) 2020-02-01
UY36095A (es) 2015-10-30
MA39770A (fr) 2015-10-29
EP3134430B1 (en) 2018-03-21
RS57153B1 (sr) 2018-07-31
NZ725476A (en) 2023-09-29
CY1120281T1 (el) 2019-07-10
US9908927B2 (en) 2018-03-06
KR20190135546A (ko) 2019-12-06
MA45069A (fr) 2019-04-03
CA3184067A1 (en) 2015-10-29
CN106459221A (zh) 2017-02-22
KR102079919B1 (ko) 2020-02-24
MY181986A (en) 2021-01-18
AU2015249649B2 (en) 2018-10-04
DK3134430T3 (en) 2018-05-22
HRP20180950T1 (hr) 2018-08-10
TW201620928A (zh) 2016-06-16
US20150337027A1 (en) 2015-11-26
TW202024123A (zh) 2020-07-01
AU2018271369B2 (en) 2020-01-02
CN111718424A (zh) 2020-09-29
JP2019162114A (ja) 2019-09-26
DOP2016000284A (es) 2017-02-15
ECSP16089579A (es) 2018-05-31
LT3134430T (lt) 2018-05-10
EP3134430A1 (en) 2017-03-01
BR112016024515A2 (pt) 2017-10-10
TR201806912T4 (tr) 2018-06-21
TWI747178B (zh) 2021-11-21
RU2699285C2 (ru) 2019-09-04
SI3134430T1 (en) 2018-05-31
PL3134430T3 (pl) 2018-08-31
PH12016502079B1 (en) 2016-12-19
JP2017513503A (ja) 2017-06-01
CN106459221B (zh) 2020-09-01
CA2946402C (en) 2023-02-28
WO2015164588A1 (en) 2015-10-29
PT3134430T (pt) 2018-04-20
US20240174731A1 (en) 2024-05-30
AR100168A1 (es) 2016-09-14
MX2019013587A (es) 2020-01-13
AU2020202247A1 (en) 2020-04-23
US20210040178A1 (en) 2021-02-11
AU2018271369A1 (en) 2018-12-20
IL248244B (en) 2020-03-31
UA118286C2 (uk) 2018-12-26
SG10202111785VA (en) 2021-12-30
MX2016013858A (es) 2017-08-02
CA2946402A1 (en) 2015-10-29
AU2015249649A1 (en) 2016-11-10
RU2016145608A3 (es) 2018-12-26
NO2776305T3 (es) 2018-01-27
RU2016145608A (ru) 2018-05-28
KR20170012257A (ko) 2017-02-02
IL248244A0 (en) 2016-11-30
SG10201806465TA (en) 2018-08-30
SG11201608767XA (en) 2016-11-29
IL272612A (en) 2020-03-31
JP6714751B2 (ja) 2020-06-24
JP6523331B2 (ja) 2019-05-29
HUE038914T2 (hu) 2018-12-28
PH12016502079A1 (en) 2016-12-19
PE20170299A1 (es) 2017-05-06
CL2016002683A1 (es) 2017-07-07
ES2672368T3 (es) 2018-06-14
BR112016024515B1 (pt) 2020-03-31
EP3366699A1 (en) 2018-08-29

Similar Documents

Publication Publication Date Title
CL2016002683A1 (es) Proteínas agonistas de los receptores de trail de cadena simple
CL2018003406A1 (es) Agonista del receptor de glucocorticoides e inmunoconjugados del mismo.
CY1119098T1 (el) Αγωνιστες fgfr1 και μεθοδοι χρησης
CY1121893T1 (el) Μορια αντισωματος κατα της τιμ-3 και χρησεις αυτων
BR112017011932A2 (pt) ?anticorpos direcionados a receptor acoplado a proteína g e métodos de uso?
DK3134123T3 (da) Il-2r-beta-selektive agonister i kombination med et anti-ctla-4-antistof eller et anti-pd-1-antistof
PE20181349A1 (es) Anticuerpos biespecificos con tetravalencia para un receptor de fnt coestimulador
DOP2018000138A (es) Nuevos anticuerpos anti-claudina y sus métodos de uso
BR112017009517A2 (pt) receptores de antígeno quimérico anti-cldn e métodos de uso
CR20150664A (es) Moduladores de los receptores de estrógeno y sus usos
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
CL2015002562A1 (es) Anticuerpos e inmunoconjugados anti-b7-h4
PE20160870A1 (es) Anticuerpos anti-claudina novedosos y metodos de uso
DK3293202T3 (da) Anti human interleukin-1 receptor accessory protein (il1rap) antibodies and uses thereof
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
CO2017003005A2 (es) Anticuerpos anti-mfi2
BR112015026122A2 (pt) métodos para usar interleucina-10 para tratar doenças e desordens
EA201600252A1 (ru) Модифицированные антитела к рецепторам антиэпидермального фактора роста и способы их использования
CL2015002724A1 (es) Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23
BR112017023131A2 (pt) anticorpos anti- fcrn
EA201790356A1 (ru) Метил- и трифторметилзамещенные пирролопиридиновые модуляторы rorc2 и способы их применения
BR112016010822A2 (pt) anticorpos específicos para fcrn
CR20150585A (es) Anticuerpos anti-igf-1r con abolición de la unión al fcrn y su utilización en el tratamiento de enfermedades oculares vasculares
UY36455A (es) Antagonistas del receptor ep3 de prostaglandinas
EA201692395A1 (ru) Новые соединения